Literature DB >> 23436971

Unusual Immunophenotypic Heterogeneity in B-Lineage ALL.

Prashant Sharma1, Vikram Narang, Jasmina Ahluwalia, Man Updesh Singh Sachdeva, Deepak Bansal.   

Abstract

Entities:  

Year:  2012        PMID: 23436971      PMCID: PMC3574498          DOI: 10.4103/0974-2727.105596

Source DB:  PubMed          Journal:  J Lab Physicians        ISSN: 0974-2727


× No keyword cloud information.
Sir, A three-year-old boy presented with fever, progressive pallor and aching limbs for the last 3 months followed by a petechial rash over the last 20 days. On examination, severe pallor, bony tenderness, petechiae over bilateral lower limbs and hepato-splenomegaly 8 cm and 4 cm below respective costal margins were noted. His haemoglobin was 34 g/L, total leukocyte count 69.3 × 10 9/L and platelet count was 14 × 109/L. A blood film showed 50% blasts and a bone marrow was performed, which revealed 93% blasts of lymphoid morphology that were myeloperoxidase-negative and PAS block-positive. Flow cytometric immunophenotyping of the bone marrow, intriguingly, revealed two distinct blast clusters on the CD45-side scatter plot [Figure 1]. The numerically smaller one (~22% of all events, P1, red in figure) with dim intensity CD45 showed a typical precursor B-lymphoblastic immunophenotype:[1] positive for CD19, CD10, CD79a, CD34 and TdT along with CD38 and HLA-DR. The other cluster comprised ~67% of all events and was CD45 negative. It showed an immunophenotype more akin to progenitor B-lymphoblasts:[12] positive for CD19, CD79a, TdT, HLA-DR and CD38 but heterogeneous (dim to negative) for CD10 and negative for CD34. Both populations were negative for all T-lineage markers (surface and cytoplasmic CD3 and surface CD4, CD7 and CD8) as well as for all myeloid and monocytic markers (cytoplasmic myeloperoxidase and surface CD13, CD14, CD15, CD16, CD33, CD64, CD117 and CD123) tested.
Figure 1

Flow cytometric analysis of the bone marrow revealed 2 blast clusters on the CD45-side scatter plot that were gated separately (a, b) Events expressing dim intensity CD45 (P1, red) were distinct from another CD45-negative cluster (P2, blue) (c) Events in P1 cluster co-expressed CD19 and CD10 while P2 was CD19-positive with heterogeneous (negative to dim) CD10 (d, e, f) Both P1 and P2 were negative for CD13, CD117, CD3 and CD33 and positive for HLA-DR (g) P1 expressed CD34, while P2 was negative (h, i, j, k) Both P1 and P2 were negative for CD22, CD64, CD14, CD11c and CD123, and both population expressed CD38, CD79a and TdT (l) The bone marrow aspirate smears showed 93% small morphologically non-descript lympho-blasts. (MGG, ×1000)

Flow cytometric analysis of the bone marrow revealed 2 blast clusters on the CD45-side scatter plot that were gated separately (a, b) Events expressing dim intensity CD45 (P1, red) were distinct from another CD45-negative cluster (P2, blue) (c) Events in P1 cluster co-expressed CD19 and CD10 while P2 was CD19-positive with heterogeneous (negative to dim) CD10 (d, e, f) Both P1 and P2 were negative for CD13, CD117, CD3 and CD33 and positive for HLA-DR (g) P1 expressed CD34, while P2 was negative (h, i, j, k) Both P1 and P2 were negative for CD22, CD64, CD14, CD11c and CD123, and both population expressed CD38, CD79a and TdT (l) The bone marrow aspirate smears showed 93% small morphologically non-descript lympho-blasts. (MGG, ×1000) A final diagnosis of B-cell acute lymphoblastic leukaemia (ALL) with mixed precursor and progenitor B-cell type blast populations was made. Molecular tests for t (9;22), t (4;11) and t (12;21) were negative. The boy was started on induction chemotherapy as per the unit's protocol and a bone marrow done at 28 days was in complete morphological remission. The 2008 WHO classification of lymphoid neoplasms recognizes several categories of acute leukaemia of ambiguous lineage with flow cytometry forming the mainstay of their identification and typing.[3] However, intra-lineage heterogeneity (i.e. multiple populations confined to either B- or T- or granulocytic or monocytic lineages) is usually not considered to be of great diagnostic significance, although they may be seen, for instance, in acute myelomonocytic leukaemia with inv (16) abnormality. The older EGIL immunophenotypic classification of ALL still carries prognostic value, therefore it is intriguing to speculate whether our case actually has a true composite neoplasm: a standard risk pre-B-CALLA-positive ALL and a poorer risk CALLA-negative pro-B-ALL.[1-4] From a converse view, immunologically distinct immature and differentiated neoplastic population have long been described in childhood ALL [5] and perhaps our case is simply a dramatic illustration of this fact. In either case, these unusual immunophenotypic findings reiterate the fact that even the extremely common B-ALL may occasionally spring a surprise for the flow cytometrist. It also presents a case for the reporting haematopathologist to maintain familiarity for the now less-and-less commonly employed EGIL classification of B-cell ALL.
  4 in total

Review 1.  Immature and differentiated neoplastic populations in acute lymphoid leukemia of childhood: biological and clinical implications.

Authors:  Z Estrov; G G Re; T F Zipf
Journal:  Leuk Lymphoma       Date:  1993-09

2.  Flow cytometry immunophenotyping of hematolymphoid neoplasia.

Authors:  Katherine R Calvo; Catharine S McCoy; Maryalice Stetler-Stevenson
Journal:  Methods Mol Biol       Date:  2011

3.  Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity.

Authors:  Andishe Attarbaschi; Georg Mann; Margit König; Manuel Steiner; Sabine Strehl; Anita Schreiberhuber; Björn Schneider; Claus Meyer; Rolf Marschalek; Arndt Borkhardt; Winfried F Pickl; Thomas Lion; Helmut Gadner; Oskar A Haas; Michael N Dworzak
Journal:  Clin Cancer Res       Date:  2006-05-15       Impact factor: 12.531

4.  Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL).

Authors:  M C Bene; G Castoldi; W Knapp; W D Ludwig; E Matutes; A Orfao; M B van't Veer
Journal:  Leukemia       Date:  1995-10       Impact factor: 11.528

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.